The first treatment worked. For eight months, a 37-year-old patient injured in a car accident had relief from severe neck pain and headaches. Then the pain returned. Physicians repeated the radiofrequency procedure with the same standard electrodes. This time, it failed. A third procedure, using an expandable electrode called Nimbus, restored relief. The 2024 case report offers a compact introduction to Stratus Medical: sometimes the difference worth investigating is the size of the area a tool can reach.
- Nimbus expands its tines to create a larger RF treatment zone.
- Stratus sells to clinicians and facilities, with training alongside the hardware.
- A Utah comparison trial stopped after insurance changes slowed enrollment.
- A $10 million Series B funds new devices and clinical work.
The repeat procedure that did not repeat the result
Radiofrequency ablation uses heat to interrupt targeted nerves carrying pain signals. Its deceptively simple challenge is reaching the right nerve adequately. The neck-pain case is suggestive because the diagnosis had been supported by a local anaesthetic block, and an earlier treatment had worked. Yet repeating the electrode configuration did not reproduce the result. Nimbus provided a larger zone of coagulation.
One patient cannot establish that one device outperforms another. The case does, however, illuminate the engineering question. If the target is small and its anatomy varies, how much certainty should depend on the physician’s placement, and how much can the instrument supply? Stratus’s flagship product tries to give the physician more coverage. A bigger treatment zone still requires a carefully chosen target.
A business built around an existing invention
Stratus’s origin is less a garage revelation than a change of ownership. In January 2020, it announced a private placement led by Med Venture Holdings and the acquisition of NimbusRF assets from Biomerics. Nimbus already had regulatory clearance and an international treatment history. Stratus was buying a product with experience in the field, then organising a business to expand its use.
Bret Boudousquie brought commercial experience to that job. Before becoming Nimbus CEO in 2019, he had led RadiaDyne, whose work included radiation-dose monitoring during cancer treatment. His earlier career included orthopaedics, spine and general surgery. These are useful credentials for selling something that must earn a place in a physician’s procedure and a hospital’s purchasing system.
The customer is a clinician; the buyer may be a practice, hospital or ambulatory surgery centre. Interventional pain specialists are central, alongside surgeons treating appropriate pain conditions. Stratus uses a direct sales team in the United States and distributors abroad. In April 2026, Osteotec announced exclusive UK distribution rights, adding an established local commercial channel.
The product that fits the equipment already in the room
Nimbus works with an RF generator and probe. Its expandable tines are the distinctive feature, but compatibility is another part of the pitch. Stratus’s 2026 catalogue lists adapter cables for eleven RF lesion generators. For a facility considering a new consumable, the ability to use existing equipment can make the purchasing conversation considerably less theatrical.
The portfolio includes reusable and disposable probes and Vesta, a standard RF cannula. Vesta’s role is revealing: Stratus introduced it in the United States for clinical situations where Nimbus’s large lesion is not indicated. The business therefore makes room for different tools rather than pretending that a bigger lesion answers every clinical question.
“Vesta allows us to deliver a more complete product offering and better serve our customers in alignment with their financial needs.”
Bret Boudousquie, July 2020
Education accompanies the products: staff in-service, clinical support, webinars and hands-on courses. These activities help clinicians learn how the hardware fits a procedure. The business model combines device sales with the repeat demand associated with disposable tools. Its economic argument rests on compatibility and procedural efficiency; neither alone establishes a particular hospital’s savings.
The trial that ran into an insurance policy
Stratus has gathered laboratory, imaging and clinical material around Nimbus. The important distinction is between demonstrating a lesion’s shape and demonstrating a patient’s outcome. A larger zone of coagulation is a physical property. Longer relief is a clinical question, influenced by diagnosis, technique and patient selection. Sales adoption cannot settle that question either.
Enrollment fell well short of the original plan. These bars say nothing about pain relief.
The University of Utah’s COBRA study was intended to compare bipolar Nimbus treatment with conventional RF for sacroiliac-joint pain. The 2023 announcement contemplated 116 participants and follow-up extending to 24 months. The registry tells a more awkward ending: actual enrollment was 20, and the study was terminated. Insurance changes slowed recruitment; the sponsor decided to stop.
That is a concrete limit on the evidence programme, rather than proof that the device failed clinically. It also supplies a lesson other medical businesses can copy: reimbursement belongs in the recruitment plan. The company’s equipment can be available, physicians can be interested, and the study can still struggle to assemble the patients it needs.
The next bet is inside the vertebra
Commercially, Stratus has momentum: it reported 212% three-year revenue growth when it ranked 483 in Deloitte’s 2024 Technology Fast 500. Its current website reports more than 500,000 Nimbus treatments. Those are different measures, and neither should be mistaken for a clinical success rate. They indicate an operating business with an installed clinical audience.
Announced uses: generator development, neurovasis BVNA technology, patents and a clinical study.
The February 2026 financing, led by Wasatch Health Partners, supports a planned RF generator and neurovasis basivertebral nerve ablation technology, as well as patents and clinical work. The company describes both new systems as not FDA cleared. Its next chapter asks whether experience with an expandable electrode can support another treatment application and a broader equipment portfolio.
For clinicians, the practical entry point is the catalogue, training and evidence relevant to their procedure. For patients, it is a conversation with their physician about the source of pain and treatment suitability. Stratus’s story makes a useful demand of both audiences: inspect the target, the tool and the evidence together.